Skip to main content
Top
Published in: Acta Diabetologica 4/2010

01-12-2010 | Review Article

Encephalopathies: the emerging diabetic complications

Author: Anders A. F. Sima

Published in: Acta Diabetologica | Issue 4/2010

Login to get access

Abstract

Diabetic encephalopathies are now accepted complications of diabetes. They appear to differ in type 1 and type 2 diabetes as to underlying mechanisms and the nature of resulting cognitive deficits. The increased incidence of Alzheimer’s disease in type 2 diabetes is associated with insulin resistance, hyperinsulinemia and hyperglycemia, and commonly accompanying attributes such as hypercholesterolemia, hypertension and obesity. The relevance of these disorders as to the emergence of dementia and Alzheimer’s disease is discussed based on epidemiological studies. The pathobiology of accumulation of β-amyloid and tau the hallmarks of Alzheimer’s disease are discussed based on experimental data. Type 1 diabetic encephalopathy is likely to increase as a result of the global increase in the incidence of type 1 diabetes and its occurrence in increasingly younger patients. Alzheimer-like changes and dementia are not prominently increased in type 1 diabetes. Instead, the type 1 diabetic encephalopathy involves learning abilities, intelligence development and memory retrieval resulting in impaired school and professional performances. The major underlying component here appears to be insulin deficiency with downstream effects on the expression of neurotrophic factors, neurotransmitters, oxidative and apoptotic stressors resulting in defects in neuronal integrity, connectivity and loss commonly occurring in the still developing brain. Recent experimental data emphasize the role of impaired central insulin action and provide information as to potential therapies. Therefore, the underlying mechanisms resulting in diabetic encephalopathies are complex and appear to differ between the two types of diabetes. Major headway has been made in our understanding of their pathobiology; however, many questions remain to be clarified. In view of the increasing incidence of both type 1 and type 2 diabetes, intensified investigations are called for to expand our understanding of these complications and to find therapeutic means by which these disastrous consequences can be prevented and modified.
Literature
1.
go back to reference Biessels GJ, Luchsinger JA (eds) (2009) Diabetes and the brain. Humana Press, New York Biessels GJ, Luchsinger JA (eds) (2009) Diabetes and the brain. Humana Press, New York
2.
go back to reference Miles WR, Root HF (1922) Psychologic tests applied in diabetic patients. Arch Intern Med 30:767–777 Miles WR, Root HF (1922) Psychologic tests applied in diabetic patients. Arch Intern Med 30:767–777
3.
go back to reference Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 58:1937–1941 Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 58:1937–1941
4.
go back to reference Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Diabetes mellitus and risk of Alzheimer’s disease and decline in cognitive function. Arch Neurol 61:661–666PubMedCrossRef Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Diabetes mellitus and risk of Alzheimer’s disease and decline in cognitive function. Arch Neurol 61:661–666PubMedCrossRef
5.
go back to reference Xu WL, Qui CX, Wahlin A, Winblad B, Fratiglioni L (2004) Diabetes mellitus and risk of dementia in the Kungshohman project: a 6 year follow-up. Neurology 63:1181–1186PubMed Xu WL, Qui CX, Wahlin A, Winblad B, Fratiglioni L (2004) Diabetes mellitus and risk of dementia in the Kungshohman project: a 6 year follow-up. Neurology 63:1181–1186PubMed
6.
go back to reference Kumari M, Marmot M (2005) Diabetes and cognitive function in a middle-aged cohort: findings from the Whitehall II study. Neurology 65:1597–1603PubMedCrossRef Kumari M, Marmot M (2005) Diabetes and cognitive function in a middle-aged cohort: findings from the Whitehall II study. Neurology 65:1597–1603PubMedCrossRef
7.
go back to reference Worrall G, Moulton E, Briffett E (1993) Effect of type II diabetes mellitus on cognitive function. J Fam Pract 36:639–643PubMed Worrall G, Moulton E, Briffett E (1993) Effect of type II diabetes mellitus on cognitive function. J Fam Pract 36:639–643PubMed
8.
go back to reference Fontbonne A, Berr C, Ducimetière P, Alpérovitch A (2001) Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. Diabetes Care 24:366–370PubMedCrossRef Fontbonne A, Berr C, Ducimetière P, Alpérovitch A (2001) Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. Diabetes Care 24:366–370PubMedCrossRef
9.
go back to reference Nguyen HT, Black SA, Roy LA, Espino DV, Markides KS (2002) Predictors of decline in MMSE scores among older Mexican Americans. J Gerontol A Biol Sci Med Sci 57:M181–M185PubMed Nguyen HT, Black SA, Roy LA, Espino DV, Markides KS (2002) Predictors of decline in MMSE scores among older Mexican Americans. J Gerontol A Biol Sci Med Sci 57:M181–M185PubMed
10.
go back to reference van Harten B, Oosterman J, Muslimovic D, van Loon BJ, Scheltens P, Weinstein HC (2007) Cognitive impairment of MRI correlates in the elderly patients with type 2 diabetes mellitus. Age Ageing 36:164–170PubMedCrossRef van Harten B, Oosterman J, Muslimovic D, van Loon BJ, Scheltens P, Weinstein HC (2007) Cognitive impairment of MRI correlates in the elderly patients with type 2 diabetes mellitus. Age Ageing 36:164–170PubMedCrossRef
11.
go back to reference Hiltunen LA, Keinänen-Kiukaanniemi SM, Läärä EM (2001) Glucose tolerance and cognitive impairment in an elderly population. Public Health 115:197–200PubMedCrossRef Hiltunen LA, Keinänen-Kiukaanniemi SM, Läärä EM (2001) Glucose tolerance and cognitive impairment in an elderly population. Public Health 115:197–200PubMedCrossRef
12.
go back to reference Wu JH, Haan MN, Liang J, Ghosh D, Gonzalez HM, Herman WH (2003) Impact of diabetes on cognitive function among older Latinos: a population-based cohort study. J Clin Epidemiol 56:686–693PubMedCrossRef Wu JH, Haan MN, Liang J, Ghosh D, Gonzalez HM, Herman WH (2003) Impact of diabetes on cognitive function among older Latinos: a population-based cohort study. J Clin Epidemiol 56:686–693PubMedCrossRef
13.
go back to reference Hassing LB, Grant MD, Hofer SM, Pedersen NL, Nilsson SE, Berg S, McClearn G, Johansson B (2004) Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study. J Int Neuropsychol Soc 10:599–607PubMedCrossRef Hassing LB, Grant MD, Hofer SM, Pedersen NL, Nilsson SE, Berg S, McClearn G, Johansson B (2004) Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study. J Int Neuropsychol Soc 10:599–607PubMedCrossRef
14.
go back to reference Ryan CM, Geckle MO (2000) Circumscribed cognitive dysfunction in middle-aged adults with type 2 diabetes. Diabetes Care 23:1486–1493PubMedCrossRef Ryan CM, Geckle MO (2000) Circumscribed cognitive dysfunction in middle-aged adults with type 2 diabetes. Diabetes Care 23:1486–1493PubMedCrossRef
15.
go back to reference Abbatecola AM, Paolisso G, Lamponi M, Bandinelli S, Lauretani F, Launer L, Ferrucci L (2004) Insulin resistance and executive dysfunction in older persons. J Am Geriatr Soc 52:1713–1718PubMedCrossRef Abbatecola AM, Paolisso G, Lamponi M, Bandinelli S, Lauretani F, Launer L, Ferrucci L (2004) Insulin resistance and executive dysfunction in older persons. J Am Geriatr Soc 52:1713–1718PubMedCrossRef
16.
go back to reference Dik MG, Jonker C, Comijs HC, Deeg DJ, Kok A, Yaffe K, Penninx BW (2007) Contributions of metabolic syndrome components to cognition in older individuals. Diabetes Care 30:2655–2660PubMedCrossRef Dik MG, Jonker C, Comijs HC, Deeg DJ, Kok A, Yaffe K, Penninx BW (2007) Contributions of metabolic syndrome components to cognition in older individuals. Diabetes Care 30:2655–2660PubMedCrossRef
17.
go back to reference Komulainen P, Lakka TA, Kivipelto M, Hassinen M, Helkala EL, Haapala I, Nissinen A, Rauramaa R (2007) Metabolic syndrome and cognitive function: a population-based follow-up study in elderly women. Dement Geriatr Cogn Disord 23:29–34PubMedCrossRef Komulainen P, Lakka TA, Kivipelto M, Hassinen M, Helkala EL, Haapala I, Nissinen A, Rauramaa R (2007) Metabolic syndrome and cognitive function: a population-based follow-up study in elderly women. Dement Geriatr Cogn Disord 23:29–34PubMedCrossRef
18.
go back to reference Convit A, Wolf OT, Tarshish C, de Leon MJ (2003) Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci USA 100:2019–2022PubMedCrossRef Convit A, Wolf OT, Tarshish C, de Leon MJ (2003) Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci USA 100:2019–2022PubMedCrossRef
19.
20.
go back to reference Schoenle EJ, Schoenle D, Molinari L, Largo RH (2002) Impaired intellectual development in children with Type I diabetes: association with HbA(1c), age at diagnosis and sex. Diabetologia 45:108–114PubMedCrossRef Schoenle EJ, Schoenle D, Molinari L, Largo RH (2002) Impaired intellectual development in children with Type I diabetes: association with HbA(1c), age at diagnosis and sex. Diabetologia 45:108–114PubMedCrossRef
21.
go back to reference Dobbing J, Sands J (1971) Vulnerability of developing brain. IX. The effect of nutritional growth retardation on the timing of the brain growth-spurt. Biol Neonate 19:363–378PubMedCrossRef Dobbing J, Sands J (1971) Vulnerability of developing brain. IX. The effect of nutritional growth retardation on the timing of the brain growth-spurt. Biol Neonate 19:363–378PubMedCrossRef
22.
go back to reference Kramer L, Fasching P, Madl C, Schneider B, Damjancic P, Waldhäusl W, Irsigler K, Grimm G (1998) Previous episodes of hypoglycemic coma are not associated with permanent cognitive brain dysfunction in IDDM patients on intensive insulin treatment. Diabetes 47:1909–1914PubMedCrossRef Kramer L, Fasching P, Madl C, Schneider B, Damjancic P, Waldhäusl W, Irsigler K, Grimm G (1998) Previous episodes of hypoglycemic coma are not associated with permanent cognitive brain dysfunction in IDDM patients on intensive insulin treatment. Diabetes 47:1909–1914PubMedCrossRef
23.
go back to reference The Diabetes Control Complications Trial/Epidemiology of Diabetes Interventions, Complications (DCCT/EDIC) Study Research Group (2007) Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 356:1842–1852CrossRef The Diabetes Control Complications Trial/Epidemiology of Diabetes Interventions, Complications (DCCT/EDIC) Study Research Group (2007) Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 356:1842–1852CrossRef
24.
go back to reference Sima AAF, Zhang W, Muzik O, Kreipke CW, Rafols JA, Hoffman WH (2009) Sequential abnormalities in type 1 diabetic encephalopathy and the effects of C-peptide. Rev Diabet Stud 6:211–222PubMedCrossRef Sima AAF, Zhang W, Muzik O, Kreipke CW, Rafols JA, Hoffman WH (2009) Sequential abnormalities in type 1 diabetic encephalopathy and the effects of C-peptide. Rev Diabet Stud 6:211–222PubMedCrossRef
25.
go back to reference Brismar T, Hyllienmark L, Ekberg K, Johansson BL (2002) Loss of temporal lobe beta power in young adults with type 1 diabetes mellitus. Neuroreport 13:2469–2473PubMedCrossRef Brismar T, Hyllienmark L, Ekberg K, Johansson BL (2002) Loss of temporal lobe beta power in young adults with type 1 diabetes mellitus. Neuroreport 13:2469–2473PubMedCrossRef
26.
go back to reference Erkinjuntti T, Ganthier S (2009) The concept of vascular cognitive impairment. Front Neurol Neurosci 24:79–85PubMedCrossRef Erkinjuntti T, Ganthier S (2009) The concept of vascular cognitive impairment. Front Neurol Neurosci 24:79–85PubMedCrossRef
27.
go back to reference Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R (2001) Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154:635–641PubMedCrossRef Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R (2001) Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154:635–641PubMedCrossRef
28.
go back to reference Peila R, Rodriguez BL, Launer LJ, Honolulu-Asia Aging Study (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies. Diabetes 51:1256–1262PubMedCrossRef Peila R, Rodriguez BL, Launer LJ, Honolulu-Asia Aging Study (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies. Diabetes 51:1256–1262PubMedCrossRef
29.
go back to reference Peila R, Rodriguez BL, White LR, Launer LJ (2004) Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 63:228–233PubMed Peila R, Rodriguez BL, White LR, Launer LJ (2004) Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 63:228–233PubMed
30.
go back to reference Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, Wolf PA, Seshadri S (2006) Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol 63:1551–1555PubMedCrossRef Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, Wolf PA, Seshadri S (2006) Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol 63:1551–1555PubMedCrossRef
31.
go back to reference Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L (2009) Uncontrolled diabetes increases the risk of Alzheimer’s disease: a population-based cohort study. Diabetologia 52:1031–1039PubMedCrossRef Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L (2009) Uncontrolled diabetes increases the risk of Alzheimer’s disease: a population-based cohort study. Diabetologia 52:1031–1039PubMedCrossRef
32.
go back to reference Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kåreholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62:1556–1560PubMedCrossRef Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kåreholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62:1556–1560PubMedCrossRef
33.
go back to reference Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K (2008) Central obesity and increased risk of dementia more than 3 decades later. Neurology 71(14):1057–1064PubMedCrossRef Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K (2008) Central obesity and increased risk of dementia more than 3 decades later. Neurology 71(14):1057–1064PubMedCrossRef
34.
go back to reference Spence JD (1996) Cerebral consequences of hypertension: where do they lead? J Hypertens Suppl 14:S139–S145PubMed Spence JD (1996) Cerebral consequences of hypertension: where do they lead? J Hypertens Suppl 14:S139–S145PubMed
36.
go back to reference Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH, Systolic Hypertension in Europe Investigators (2002) The prevention of dementia with anti-hypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) Study. Arch Int Med 162:2046–2052CrossRef Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH, Systolic Hypertension in Europe Investigators (2002) The prevention of dementia with anti-hypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) Study. Arch Int Med 162:2046–2052CrossRef
37.
go back to reference Li N-C, Lee A, Whitmer RA, Kivipelto M, Lowler E, Kazis LE, Wolozin B (2010) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: a prospective cohort analysis. BMJ 340:b5465. doi:10:1136/baijb5465 PubMedCrossRef Li N-C, Lee A, Whitmer RA, Kivipelto M, Lowler E, Kazis LE, Wolozin B (2010) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: a prospective cohort analysis. BMJ 340:b5465. doi:10:​1136/​baijb5465 PubMedCrossRef
38.
go back to reference Tezapsidis N, Johnston JM, Smith MA, Ashford JW, Casadesus G, Robakis NK, Wolozin B, Perry G, Zu X, Greco SJ, Sarkar S (2009) Leptin: a novel therapeutic strategy for Alzheimer’s disease. J Alzheimer Dis 16:731–740 Tezapsidis N, Johnston JM, Smith MA, Ashford JW, Casadesus G, Robakis NK, Wolozin B, Perry G, Zu X, Greco SJ, Sarkar S (2009) Leptin: a novel therapeutic strategy for Alzheimer’s disease. J Alzheimer Dis 16:731–740
39.
go back to reference Nourhashémi F, Deschamps V, Larrieu S, Letenneur L, Dartigues JF, Barberger-Gateau P, PAQU ID Study. Personnes Agées Quid (2003) Body mass index and incidence of dementia: the PAQUID study. Neurology 60:117–119PubMedCrossRef Nourhashémi F, Deschamps V, Larrieu S, Letenneur L, Dartigues JF, Barberger-Gateau P, PAQU ID Study. Personnes Agées Quid (2003) Body mass index and incidence of dementia: the PAQUID study. Neurology 60:117–119PubMedCrossRef
40.
go back to reference Henderson VW, Guthrie JR, Dennerstein L (2003) Serum lipids and memory in a population based cohort of middle age women. J Neurol Neurosurg Psychiatry 74:1530–1535PubMedCrossRef Henderson VW, Guthrie JR, Dennerstein L (2003) Serum lipids and memory in a population based cohort of middle age women. J Neurol Neurosurg Psychiatry 74:1530–1535PubMedCrossRef
41.
go back to reference Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM (2002) Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 33:21–25PubMedCrossRef Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM (2002) Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 33:21–25PubMedCrossRef
42.
go back to reference de Leeuw FE, de Groot JC, Achten E, Oudkerk M, Ramos LM, Heijboer R, Hofman A, Jolles J, van Gijn J, Breteler MM (2001) Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 70:9–14PubMedCrossRef de Leeuw FE, de Groot JC, Achten E, Oudkerk M, Ramos LM, Heijboer R, Hofman A, Jolles J, van Gijn J, Breteler MM (2001) Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 70:9–14PubMedCrossRef
43.
go back to reference Scahill RI, Frost C, Jenkins R, Whitwell JL, Rossor MN, Fox NC (2003) A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol 60:989–994PubMedCrossRef Scahill RI, Frost C, Jenkins R, Whitwell JL, Rossor MN, Fox NC (2003) A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol 60:989–994PubMedCrossRef
44.
go back to reference Gouw AA, van der Flier WM, Fazekas F, van Straaten EC, Pantoni L, Poggesi A, Inzitari D, Erkinjuntti T, Wahlund LO, Waldemar G, Schmidt R, Scheltens P, Barkhof F, LADIS Study Group (2008) Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke 39:1414–1420PubMedCrossRef Gouw AA, van der Flier WM, Fazekas F, van Straaten EC, Pantoni L, Poggesi A, Inzitari D, Erkinjuntti T, Wahlund LO, Waldemar G, Schmidt R, Scheltens P, Barkhof F, LADIS Study Group (2008) Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke 39:1414–1420PubMedCrossRef
45.
go back to reference Jongen C, van der Grond J, Kappelle LJ, Biessels GJ, Viergever MA, Pluim JP, Utrecht Diabetic Encephalopathy Study Group (2007) Automated measurement of brain and white matter lesion volume in type 2 diabetes mellitus. Diabet Med 24:166–171CrossRef Jongen C, van der Grond J, Kappelle LJ, Biessels GJ, Viergever MA, Pluim JP, Utrecht Diabetic Encephalopathy Study Group (2007) Automated measurement of brain and white matter lesion volume in type 2 diabetes mellitus. Diabet Med 24:166–171CrossRef
46.
go back to reference van Harten B, Oosterman JM, Potter van Loon BJ, Scheltens P, Weinstein HC (2007) Brain lesions on MRI in elderly patients with type 2 diabetes mellitus. Eur Neurol 57:70–74PubMedCrossRef van Harten B, Oosterman JM, Potter van Loon BJ, Scheltens P, Weinstein HC (2007) Brain lesions on MRI in elderly patients with type 2 diabetes mellitus. Eur Neurol 57:70–74PubMedCrossRef
47.
go back to reference den Heijer T, Vermeer SE, van Dijk EJ, Prins ND, Koudstaal PJ, Hofman A, Breteler MM (2003) Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 46:1604–1610CrossRef den Heijer T, Vermeer SE, van Dijk EJ, Prins ND, Koudstaal PJ, Hofman A, Breteler MM (2003) Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 46:1604–1610CrossRef
48.
go back to reference Korf ES, White LR, Scheltens P, Launer LJ (2006) Brain aging in very old men with type 2 diabetes: the Honolulu-Asia Aging Study. Diabetes Care 29:2268–2274PubMedCrossRef Korf ES, White LR, Scheltens P, Launer LJ (2006) Brain aging in very old men with type 2 diabetes: the Honolulu-Asia Aging Study. Diabetes Care 29:2268–2274PubMedCrossRef
49.
go back to reference Korf ES, van Straaten EC, de Leeuw FE, van der Flier WM, Barkhof F, Pantoni L, Basile AM, Inzitari D, Erkinjuntti T, Wahlund LO, Rostrup E, Schmidt R, Fazekas F, Scheltens P, LADIS Study Group (2007) Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. Diabet Med 24:166–171PubMedCrossRef Korf ES, van Straaten EC, de Leeuw FE, van der Flier WM, Barkhof F, Pantoni L, Basile AM, Inzitari D, Erkinjuntti T, Wahlund LO, Rostrup E, Schmidt R, Fazekas F, Scheltens P, LADIS Study Group (2007) Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. Diabet Med 24:166–171PubMedCrossRef
50.
go back to reference Manschot SM, Brands AM, van der Grond J, Kessels RP, Algra A, Kappelle LJ, Biessels GJ, Utrecht Diabetic Encephalopathy Study Group (2006) Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 55:1106–1113PubMedCrossRef Manschot SM, Brands AM, van der Grond J, Kessels RP, Algra A, Kappelle LJ, Biessels GJ, Utrecht Diabetic Encephalopathy Study Group (2006) Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 55:1106–1113PubMedCrossRef
51.
go back to reference Akisaki T, Sakurai T, Takata T, Umegaki H, Araki A, Mizuno S, Tanaka S, Ohashi Y, Iguchi A, Yokono K, Ito H (2006) Cognitive dysfunction associates with white matter hyperintensities and subcortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus Japanese elderly diabetes intervention trial (J-EDIT). Diabetes Metab Res Rev 22:376–384PubMedCrossRef Akisaki T, Sakurai T, Takata T, Umegaki H, Araki A, Mizuno S, Tanaka S, Ohashi Y, Iguchi A, Yokono K, Ito H (2006) Cognitive dysfunction associates with white matter hyperintensities and subcortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus Japanese elderly diabetes intervention trial (J-EDIT). Diabetes Metab Res Rev 22:376–384PubMedCrossRef
52.
go back to reference de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, Breteler MM (2002) Hypertension and cerebral white matter lesions in a prospective cohort study. Brain 125:765–772PubMedCrossRef de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, Breteler MM (2002) Hypertension and cerebral white matter lesions in a prospective cohort study. Brain 125:765–772PubMedCrossRef
53.
go back to reference Knopman DS, Mosley TH, Catellier DJ, Sharrett AR, Atherosclerosis Risk in Communities (ARIC) Study (2005) Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort. Neurology 65:876–881PubMedCrossRef Knopman DS, Mosley TH, Catellier DJ, Sharrett AR, Atherosclerosis Risk in Communities (ARIC) Study (2005) Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort. Neurology 65:876–881PubMedCrossRef
54.
go back to reference Li Z-G, Zhang W, Sima AAF (2005) The role of impaired insulin/IGF action in primary diabetic encephalopathy. Brain Res 1037:12–24PubMedCrossRef Li Z-G, Zhang W, Sima AAF (2005) The role of impaired insulin/IGF action in primary diabetic encephalopathy. Brain Res 1037:12–24PubMedCrossRef
55.
go back to reference de la Monte SM, Wands JR (2008) Alzheimer’s disease is type 3 diabetes-evidence reviewed. J Diabet Sci Tech 2:1101–1113 de la Monte SM, Wands JR (2008) Alzheimer’s disease is type 3 diabetes-evidence reviewed. J Diabet Sci Tech 2:1101–1113
56.
go back to reference Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, Creager MA (1998) Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97:1695–1701PubMed Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, Creager MA (1998) Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97:1695–1701PubMed
57.
go back to reference Tesfomariam B, Brown ML, Cohen RA (1991) Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 87:1643–1648CrossRef Tesfomariam B, Brown ML, Cohen RA (1991) Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 87:1643–1648CrossRef
58.
go back to reference Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H (2000) High glucose level and free fatty acid stimulate reactive oxygen species production through protein-kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49:1939–1945PubMedCrossRef Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H (2000) High glucose level and free fatty acid stimulate reactive oxygen species production through protein-kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49:1939–1945PubMedCrossRef
59.
go back to reference Hoyer S (2004) Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv Exp Med Biol 541:135–152PubMed Hoyer S (2004) Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv Exp Med Biol 541:135–152PubMed
60.
go back to reference Hoyer S (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490:115–125PubMedCrossRef Hoyer S (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490:115–125PubMedCrossRef
61.
go back to reference Li Z-G, Zhang W, Sima AAF (2007) Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 56:1817–1824PubMedCrossRef Li Z-G, Zhang W, Sima AAF (2007) Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 56:1817–1824PubMedCrossRef
62.
go back to reference Craft S (2007) Insulin resistance and Alzheimer’s disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 4:147–152PubMedCrossRef Craft S (2007) Insulin resistance and Alzheimer’s disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 4:147–152PubMedCrossRef
63.
go back to reference Li Z-G, Qiang X, Sima AAF (2001) Grunberger G: C-peptide attenuates protein tyrosine phosphatase activity and enhances glycogen synthesis in L6 myoblasts. Biochem Biophys Res Com 26:615–619CrossRef Li Z-G, Qiang X, Sima AAF (2001) Grunberger G: C-peptide attenuates protein tyrosine phosphatase activity and enhances glycogen synthesis in L6 myoblasts. Biochem Biophys Res Com 26:615–619CrossRef
64.
go back to reference Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J, Tuor UI, Glazner G, Hanson LR, Frey WH 2nd, Toth C (2008) Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 131:3311–3334PubMedCrossRef Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J, Tuor UI, Glazner G, Hanson LR, Frey WH 2nd, Toth C (2008) Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 131:3311–3334PubMedCrossRef
65.
go back to reference Sima AAF, Kamiya H, Li Z-G (2004) Insulin, C-peptide hyperglycemia and central nervous system complications in diabetes. Eur J Pharmacol 490:187–197PubMedCrossRef Sima AAF, Kamiya H, Li Z-G (2004) Insulin, C-peptide hyperglycemia and central nervous system complications in diabetes. Eur J Pharmacol 490:187–197PubMedCrossRef
66.
go back to reference Pierson CR, Zhang W, Murakawa Y, Sima AAF (2002) Early gene responses of trophic factors differ in nerve regeneration in type 1 and type 2 diabetic neuropathy. J Neuropathol Exp Neurol 61:857–871PubMed Pierson CR, Zhang W, Murakawa Y, Sima AAF (2002) Early gene responses of trophic factors differ in nerve regeneration in type 1 and type 2 diabetic neuropathy. J Neuropathol Exp Neurol 61:857–871PubMed
67.
go back to reference Xu G, Sima AAF (2001) Altered immediate early gene expression is impaired in diabetic nerve: implications in regeneration. J Neuropathol Exp Neurol 60(10):972–983PubMed Xu G, Sima AAF (2001) Altered immediate early gene expression is impaired in diabetic nerve: implications in regeneration. J Neuropathol Exp Neurol 60(10):972–983PubMed
68.
go back to reference Yerneni KK, Bai W, Khan BV, Medford RM, Natarajan R (1999) Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 48:855–864PubMedCrossRef Yerneni KK, Bai W, Khan BV, Medford RM, Natarajan R (1999) Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 48:855–864PubMedCrossRef
69.
go back to reference Luppi P, Cifarelli V, Tse H, Piganelli J, Trucco M (2008) Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-kappaB pathway. Diabetologia 51:1534–1543PubMedCrossRef Luppi P, Cifarelli V, Tse H, Piganelli J, Trucco M (2008) Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-kappaB pathway. Diabetologia 51:1534–1543PubMedCrossRef
70.
go back to reference Sima AAF, Zhang W, Kreipke CW, Rafols JA, Hoffman WH (2009) Inflammation in diabetic encephalopathy is prevented by C-peptide. Rev Diabet Stud 6:37–42PubMedCrossRef Sima AAF, Zhang W, Kreipke CW, Rafols JA, Hoffman WH (2009) Inflammation in diabetic encephalopathy is prevented by C-peptide. Rev Diabet Stud 6:37–42PubMedCrossRef
71.
go back to reference Li Z-G, Zhang W, Sima AAF (2003) C-peptide enhances insulin-mediated cell growth and protection against high glucose induced apoptosis in SH-SY5Y cells. Diabetes Metab Res Rev 19:375–385PubMedCrossRef Li Z-G, Zhang W, Sima AAF (2003) C-peptide enhances insulin-mediated cell growth and protection against high glucose induced apoptosis in SH-SY5Y cells. Diabetes Metab Res Rev 19:375–385PubMedCrossRef
73.
go back to reference Balakrishnan S, Mathew J, Paulose CS (2010) Cholinergic and glutamergic receptor functional regulation in long-term, low dose somatotropin and insulin treatment to ageing rats: rejuvenation of brain function. Mol Cell Endocrinol 314:23–30PubMedCrossRef Balakrishnan S, Mathew J, Paulose CS (2010) Cholinergic and glutamergic receptor functional regulation in long-term, low dose somatotropin and insulin treatment to ageing rats: rejuvenation of brain function. Mol Cell Endocrinol 314:23–30PubMedCrossRef
74.
go back to reference Conner JM, Franks KM, Titterness AK, Russell K, Merrill DA, Christie BR, Sejnowski TJ, Tuszynski MH (2009) NGF is essential for hippocampal plasticity and learning. J Neurosci 35:10883–10889CrossRef Conner JM, Franks KM, Titterness AK, Russell K, Merrill DA, Christie BR, Sejnowski TJ, Tuszynski MH (2009) NGF is essential for hippocampal plasticity and learning. J Neurosci 35:10883–10889CrossRef
76.
go back to reference Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, Tweedie D, Perry T, Mattson MP, Kapogiannis D, Sambamurti K, Lahiri DK, Greig NH (2010) GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J Alzheimers Dis 19:1205–1219PubMed Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, Tweedie D, Perry T, Mattson MP, Kapogiannis D, Sambamurti K, Lahiri DK, Greig NH (2010) GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J Alzheimers Dis 19:1205–1219PubMed
77.
go back to reference Tuppo EE, Arias HR (2005) The role of inflammation in Alzheimer’s disease. Int J Biochem Cell Biol 37:289–305PubMedCrossRef Tuppo EE, Arias HR (2005) The role of inflammation in Alzheimer’s disease. Int J Biochem Cell Biol 37:289–305PubMedCrossRef
78.
go back to reference Chen GJ, Xu J, Lahousse SA, Caggiano NL, de la Monte SM (2003) Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection. J Alzheimers Dis 5:209–228PubMed Chen GJ, Xu J, Lahousse SA, Caggiano NL, de la Monte SM (2003) Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection. J Alzheimers Dis 5:209–228PubMed
79.
go back to reference Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 100:4162–4167PubMedCrossRef Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 100:4162–4167PubMedCrossRef
80.
81.
go back to reference Ehehalt R, Keller P, Haass C, Thiele C, Simons K (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160:113–123PubMedCrossRef Ehehalt R, Keller P, Haass C, Thiele C, Simons K (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160:113–123PubMedCrossRef
82.
go back to reference Cordy JM, Hooper NM, Turner AJ (2006) The involvement of lipid rafts in Alzheimer’s disease. Mol Membr Biol 23:111–122PubMedCrossRef Cordy JM, Hooper NM, Turner AJ (2006) The involvement of lipid rafts in Alzheimer’s disease. Mol Membr Biol 23:111–122PubMedCrossRef
83.
go back to reference Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, Younkin LH, Younkin SG, Golde TE (2002) Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis 9:11–23PubMedCrossRef Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, Younkin LH, Younkin SG, Golde TE (2002) Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis 9:11–23PubMedCrossRef
84.
go back to reference Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ (2003) Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci USA 100:11735–11740PubMedCrossRef Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ (2003) Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci USA 100:11735–11740PubMedCrossRef
85.
go back to reference Sima AAF, Zhang W (2010) Caveolin 1 plays a central role in amyloidogenesis in type 2 diabetes (abstract). XXth Neurodiab, EASD Stockholm Sima AAF, Zhang W (2010) Caveolin 1 plays a central role in amyloidogenesis in type 2 diabetes (abstract). XXth Neurodiab, EASD Stockholm
86.
go back to reference Selkoe DJ (2001) Alzheimer’s disease genes, proteins and therapy. Physiol Rev 81:741–766PubMed Selkoe DJ (2001) Alzheimer’s disease genes, proteins and therapy. Physiol Rev 81:741–766PubMed
87.
go back to reference Papassotiropoulos A, Wollmer MA, Tsolaki M, Brunner F, Molyva D, Lütjohann D, Nitsch RM, Hock C (2005) A cluster of cholesterol-related genes confers susceptibility for Alzheimer’s disease. J Clin Psychiatry 66:940–947PubMedCrossRef Papassotiropoulos A, Wollmer MA, Tsolaki M, Brunner F, Molyva D, Lütjohann D, Nitsch RM, Hock C (2005) A cluster of cholesterol-related genes confers susceptibility for Alzheimer’s disease. J Clin Psychiatry 66:940–947PubMedCrossRef
88.
go back to reference Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM (2002) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 97:2892–2897CrossRef Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM (2002) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 97:2892–2897CrossRef
89.
go back to reference Petanceska SS, Gandy S (1999) The phosphatidylinositol 3-kinase inhibitor wortmannin alters the metabolism of the Alzheimer’s amyloid precursor protein. J Neurochem 73:2316–2320PubMedCrossRef Petanceska SS, Gandy S (1999) The phosphatidylinositol 3-kinase inhibitor wortmannin alters the metabolism of the Alzheimer’s amyloid precursor protein. J Neurochem 73:2316–2320PubMedCrossRef
90.
go back to reference Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA (2000) Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model. Neurobiol Dis 7:321–331PubMedCrossRef Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA (2000) Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model. Neurobiol Dis 7:321–331PubMedCrossRef
91.
go back to reference Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95:6460–6464PubMedCrossRef Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95:6460–6464PubMedCrossRef
92.
go back to reference Jurevics H, Morell P (1995) Cholesterol for synthesis of myelin is made locally, not imported into brain. J Neurochem 64:895–901PubMedCrossRef Jurevics H, Morell P (1995) Cholesterol for synthesis of myelin is made locally, not imported into brain. J Neurochem 64:895–901PubMedCrossRef
93.
go back to reference de Pablo F, de la Rosa EJ (1995) The developing CNS: a scenario for the action of proinsulin, insulin and insulin-like growth factors. Trends Neurosci 18:143–150PubMedCrossRef de Pablo F, de la Rosa EJ (1995) The developing CNS: a scenario for the action of proinsulin, insulin and insulin-like growth factors. Trends Neurosci 18:143–150PubMedCrossRef
94.
go back to reference Sima AAF, Kamiya H (2008) Is C-peptide replacement the missing link for successful treatment of neurological complications in type 1 diabetes? Curr Drug Targets 9:37–46PubMedCrossRef Sima AAF, Kamiya H (2008) Is C-peptide replacement the missing link for successful treatment of neurological complications in type 1 diabetes? Curr Drug Targets 9:37–46PubMedCrossRef
95.
go back to reference Sima AAF, Li Z-G (2005) The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetes. Diabetes 54:1497–1505PubMedCrossRef Sima AAF, Li Z-G (2005) The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetes. Diabetes 54:1497–1505PubMedCrossRef
96.
go back to reference Uetsuki T, Takemoto K, Nishimura I, Okamoto M, Niinobe M, Momoi T, Miura M, Yoshikawa K (1999) Activation of neuronal caspase-3 by intracellular accumulation of wild-type Alzheimer amyloid precursor protein. J Neurosci 19:6955–6964PubMed Uetsuki T, Takemoto K, Nishimura I, Okamoto M, Niinobe M, Momoi T, Miura M, Yoshikawa K (1999) Activation of neuronal caspase-3 by intracellular accumulation of wild-type Alzheimer amyloid precursor protein. J Neurosci 19:6955–6964PubMed
97.
go back to reference Matsui T, Ramasamy K, Ingelsson M, Fukumoto H, Conrad C, Frosch MP, Irizarry MC, Yuan J, Hyman BT (2006) Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer disease: relationship to formic acid extractable abeta42 levels. J Neuropathol Exp Neurol 65:508–516PubMedCrossRef Matsui T, Ramasamy K, Ingelsson M, Fukumoto H, Conrad C, Frosch MP, Irizarry MC, Yuan J, Hyman BT (2006) Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer disease: relationship to formic acid extractable abeta42 levels. J Neuropathol Exp Neurol 65:508–516PubMedCrossRef
98.
go back to reference Anonymous Author (2010) Acetyl-l-carnitine monograph. Altern Med Rev 15:76–83 Anonymous Author (2010) Acetyl-l-carnitine monograph. Altern Med Rev 15:76–83
99.
go back to reference Zanelli SA, Solenski NJ, Rosenthal RE, Fiskum G (2005) Mechanisms of ischemic neuroprotection by acetyl-l-carnitine. Ann NY Acad Sci 1053:153–161PubMedCrossRef Zanelli SA, Solenski NJ, Rosenthal RE, Fiskum G (2005) Mechanisms of ischemic neuroprotection by acetyl-l-carnitine. Ann NY Acad Sci 1053:153–161PubMedCrossRef
100.
go back to reference Sima AAF (2009) Pathobiology of diabetic encephalopathy in animal models. In: Biessels GJ, Luchsinger JA (eds) Diabetes and the brain. Humana Press, Clifton, pp 409–431CrossRef Sima AAF (2009) Pathobiology of diabetic encephalopathy in animal models. In: Biessels GJ, Luchsinger JA (eds) Diabetes and the brain. Humana Press, Clifton, pp 409–431CrossRef
101.
go back to reference Kim B, Backus C, Oh SS, Hayes JM, Feldman EL (2009) Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 150:5294–5301PubMedCrossRef Kim B, Backus C, Oh SS, Hayes JM, Feldman EL (2009) Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 150:5294–5301PubMedCrossRef
102.
go back to reference Ryan C, Vega A, Drash A (1985) Cognitive deficits in adolescents who developed diabetes early in life. Pediatrics 75:921–927PubMed Ryan C, Vega A, Drash A (1985) Cognitive deficits in adolescents who developed diabetes early in life. Pediatrics 75:921–927PubMed
103.
go back to reference Northam EA, Anderson PJ, Jacobs R, Hughes M, Warne GL, Werther GA (2001) Neuropsychological profiles of children with type 1 diabetes 6 years after disease onset. Diabetes Care 24:1541–1546PubMedCrossRef Northam EA, Anderson PJ, Jacobs R, Hughes M, Warne GL, Werther GA (2001) Neuropsychological profiles of children with type 1 diabetes 6 years after disease onset. Diabetes Care 24:1541–1546PubMedCrossRef
104.
go back to reference Northam EA, Rankins D, Lin A, Wellard RM, Pell GS, Finch SJ, Werther GA, Cameron FJ (2009) Central nervous system function in youth with type 1 diabetes 12 years after disease onset. Diabetes Care 32:445–450PubMedCrossRef Northam EA, Rankins D, Lin A, Wellard RM, Pell GS, Finch SJ, Werther GA, Cameron FJ (2009) Central nervous system function in youth with type 1 diabetes 12 years after disease onset. Diabetes Care 32:445–450PubMedCrossRef
105.
go back to reference Ryan CM (2006) Why is cognitive dysfunction associated with the development of diabetes early in life? The diathesis hypothesis. Pediatr Diabetes 7:289–297PubMedCrossRef Ryan CM (2006) Why is cognitive dysfunction associated with the development of diabetes early in life? The diathesis hypothesis. Pediatr Diabetes 7:289–297PubMedCrossRef
106.
go back to reference Fox MA, Chen RS, Holmes CS (2003) Gender differences in memory and learning in children with insulin-dependent diabetes mellitus (IDDM) over a 4-year follow-up interval. J Pediatr Psychol 28:569–578PubMedCrossRef Fox MA, Chen RS, Holmes CS (2003) Gender differences in memory and learning in children with insulin-dependent diabetes mellitus (IDDM) over a 4-year follow-up interval. J Pediatr Psychol 28:569–578PubMedCrossRef
107.
go back to reference Austin EJ, Deary IJ (1999) Effects of repeated hypoglycemia on cognitive function: a psychometrically validated reanalysis of the diabetes control and complications trial data. Diabetes Care 22:1273–1277PubMedCrossRef Austin EJ, Deary IJ (1999) Effects of repeated hypoglycemia on cognitive function: a psychometrically validated reanalysis of the diabetes control and complications trial data. Diabetes Care 22:1273–1277PubMedCrossRef
108.
go back to reference Ehehalt S, Blumenstock G, Willasch AM, Hub R, Ranke MB, Neu A, DIARY-Study Group Baden-Württemberg (2008) Continuous rise in incidence of childhood type 1 diabetes in Germany. Diabet Med 25:755–757PubMedCrossRef Ehehalt S, Blumenstock G, Willasch AM, Hub R, Ranke MB, Neu A, DIARY-Study Group Baden-Württemberg (2008) Continuous rise in incidence of childhood type 1 diabetes in Germany. Diabet Med 25:755–757PubMedCrossRef
109.
go back to reference Harjutsalo V, Sjöberg L, Tuomilehto J (2008) Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 371:1777–1782PubMedCrossRef Harjutsalo V, Sjöberg L, Tuomilehto J (2008) Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 371:1777–1782PubMedCrossRef
110.
go back to reference Kumar P, Krishna P, Reddy SC, Gurappa M, Aravind SR, Munichoodappa C (2008) Incidence of type 1 diabetes mellitus and associated complications among children and young adults: results from Karnataka Diabetes Registry 1995–2008. J Ind Med Assoc 106:708–711 Kumar P, Krishna P, Reddy SC, Gurappa M, Aravind SR, Munichoodappa C (2008) Incidence of type 1 diabetes mellitus and associated complications among children and young adults: results from Karnataka Diabetes Registry 1995–2008. J Ind Med Assoc 106:708–711
111.
go back to reference EURODIAB ACE Study Group (2000) Variation and trends in incidence of childhood diabetes in Europe. Lancet 355:873–876CrossRef EURODIAB ACE Study Group (2000) Variation and trends in incidence of childhood diabetes in Europe. Lancet 355:873–876CrossRef
112.
go back to reference Ho MS, Weller NJ, Ives FJ, Carne CL, Murray K, Vanden Driesen RI, Nguyen TP, Robins PD, Bulsara M, Davis EA, Jones TW (2008) Prevalence of structural central nervous system abnormalities in early-onset type 1 diabetes mellitus. J Pediatr 153:385–390PubMedCrossRef Ho MS, Weller NJ, Ives FJ, Carne CL, Murray K, Vanden Driesen RI, Nguyen TP, Robins PD, Bulsara M, Davis EA, Jones TW (2008) Prevalence of structural central nervous system abnormalities in early-onset type 1 diabetes mellitus. J Pediatr 153:385–390PubMedCrossRef
113.
go back to reference Musen G, Lyoo IK, Sparks CR, Weinger K, Hwang J, Ryan CM, Jimerson DC, Hennen J, Renshaw PF, Jacobson AM (2006) Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes 55:326–333PubMedCrossRef Musen G, Lyoo IK, Sparks CR, Weinger K, Hwang J, Ryan CM, Jimerson DC, Hennen J, Renshaw PF, Jacobson AM (2006) Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes 55:326–333PubMedCrossRef
114.
go back to reference Hoffman WH, Artlett CM, Zhang W, Kreipke CW, Passmore GG, Rafols JA, Sima AAF (2008) Receptor for advanced glycation end products and neuronal deficit in the fatal brain edema of diabetic ketoacidosis. Brain Res 1238:154–162PubMedCrossRef Hoffman WH, Artlett CM, Zhang W, Kreipke CW, Passmore GG, Rafols JA, Sima AAF (2008) Receptor for advanced glycation end products and neuronal deficit in the fatal brain edema of diabetic ketoacidosis. Brain Res 1238:154–162PubMedCrossRef
115.
go back to reference van Duinkerken E, Klein M, Schoonenboom NS, Hoogma RP, Moll AC, Snoek FJ, Stam CJ, Diamant M (2009) Functional brain connectivity and neurocognitive functioning in patients with long-standing type 1 diabetes with and without microvascular complications: a magnetoencephalography study. Diabetes 58:2335–2343PubMedCrossRef van Duinkerken E, Klein M, Schoonenboom NS, Hoogma RP, Moll AC, Snoek FJ, Stam CJ, Diamant M (2009) Functional brain connectivity and neurocognitive functioning in patients with long-standing type 1 diabetes with and without microvascular complications: a magnetoencephalography study. Diabetes 58:2335–2343PubMedCrossRef
116.
go back to reference Wilkins TJ (2001) The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 44:914–922CrossRef Wilkins TJ (2001) The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 44:914–922CrossRef
117.
go back to reference Dabelea D (2009) The accelerating epidemic of childhood diabetes. Lancet 372:1999–2000CrossRef Dabelea D (2009) The accelerating epidemic of childhood diabetes. Lancet 372:1999–2000CrossRef
118.
go back to reference Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB (2009) Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301:2129–2140PubMedCrossRef Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB (2009) Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301:2129–2140PubMedCrossRef
119.
go back to reference Salem MA, Matta LF, Tantawy AA, Hussein M, Gad GI (2002) Single photon emission tomography (SPECT) study of regional cerebral blood flow in normoalbuminuric children and adolescents with type 1 diabetes. 3:155–162 Salem MA, Matta LF, Tantawy AA, Hussein M, Gad GI (2002) Single photon emission tomography (SPECT) study of regional cerebral blood flow in normoalbuminuric children and adolescents with type 1 diabetes. 3:155–162
120.
go back to reference Perantie DC, Wu J, Koller JM, Lim A, Warren SL, Black KJ, Sadler M, White NH, Hershey T (2007) Regional brain volume differences associated with hyperglycemia and severe hypoglycemia in youth with type 1 diabetes. Diabetes Care 30:2331–2337PubMedCrossRef Perantie DC, Wu J, Koller JM, Lim A, Warren SL, Black KJ, Sadler M, White NH, Hershey T (2007) Regional brain volume differences associated with hyperglycemia and severe hypoglycemia in youth with type 1 diabetes. Diabetes Care 30:2331–2337PubMedCrossRef
121.
go back to reference Malone JI, Hanna S, Saporta S, Mervis RF, Park CR, Chong L, Diamond DM (2008) Hyperglycemia not hypoglycemia alters neuronal dendrites and impairs spatial memory. Pediatr Diab 9:531–539CrossRef Malone JI, Hanna S, Saporta S, Mervis RF, Park CR, Chong L, Diamond DM (2008) Hyperglycemia not hypoglycemia alters neuronal dendrites and impairs spatial memory. Pediatr Diab 9:531–539CrossRef
122.
go back to reference Biessels GJ, Kamal A, Ramakers GM, Urban IJ, Spruijt BM, Erkelens DW, Gispen WH (1996) Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes 45:1259–1266PubMedCrossRef Biessels GJ, Kamal A, Ramakers GM, Urban IJ, Spruijt BM, Erkelens DW, Gispen WH (1996) Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes 45:1259–1266PubMedCrossRef
123.
go back to reference Biessels GJ, Kamal A, Urban IJ, Spruijt BM, Erkelens DW, Gispen WH (1998) Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Res 800:125–135PubMedCrossRef Biessels GJ, Kamal A, Urban IJ, Spruijt BM, Erkelens DW, Gispen WH (1998) Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Res 800:125–135PubMedCrossRef
124.
go back to reference Sima AAF, Yagihashi S (1986) Central-peripheral distal axonopathy in the spontaneously diabetic BB- rat: Ultrastructural and morphometric findings. Diab Res Clin Pract 1:289–298CrossRef Sima AAF, Yagihashi S (1986) Central-peripheral distal axonopathy in the spontaneously diabetic BB- rat: Ultrastructural and morphometric findings. Diab Res Clin Pract 1:289–298CrossRef
125.
go back to reference Kamijo M, Cherian PV, Sima AAF (1993) The preventive effect of aldose reductase inhibition on diabetic optic neuropathy in the BB/W-rat. Diabetologia 36:893–898PubMedCrossRef Kamijo M, Cherian PV, Sima AAF (1993) The preventive effect of aldose reductase inhibition on diabetic optic neuropathy in the BB/W-rat. Diabetologia 36:893–898PubMedCrossRef
126.
go back to reference Biessels GJ (2007) Diabetic encephalopathy. In: Veves A, Malik RA (eds) Diabetic neuropathy—clinical management. Humana Press, Totowa, p 18 Biessels GJ (2007) Diabetic encephalopathy. In: Veves A, Malik RA (eds) Diabetic neuropathy—clinical management. Humana Press, Totowa, p 18
127.
go back to reference Crusio WE, Schwegler H (2005) Learning spatial orientation tasks in the radial-maze and structural variation in the hippocampus in inbred mice. Behav Brain Funct 1:1–3CrossRef Crusio WE, Schwegler H (2005) Learning spatial orientation tasks in the radial-maze and structural variation in the hippocampus in inbred mice. Behav Brain Funct 1:1–3CrossRef
128.
go back to reference Wiener SI, Paul CA, Eichenbaum H (1989) Spatial and behavioral correlates to hippocampal neuronal activity. J Neurosci 9:2737–2763PubMed Wiener SI, Paul CA, Eichenbaum H (1989) Spatial and behavioral correlates to hippocampal neuronal activity. J Neurosci 9:2737–2763PubMed
129.
go back to reference Blanchard JG, Duncan PM (1997) Effect of the combination of insulin, glucose and scopolamine on radial arm maze performance. Pharmacol Biochem Behav 58:209–214PubMedCrossRef Blanchard JG, Duncan PM (1997) Effect of the combination of insulin, glucose and scopolamine on radial arm maze performance. Pharmacol Biochem Behav 58:209–214PubMedCrossRef
130.
go back to reference Grunberger G, Qiang X, Li Z-G, Mathews ST, Sbriessa D, Shisheva A, Sima AAF (2001) Molecular basis for the insulinomimetic effects of C-peptide. Diabetologia 44:1247–1257PubMedCrossRef Grunberger G, Qiang X, Li Z-G, Mathews ST, Sbriessa D, Shisheva A, Sima AAF (2001) Molecular basis for the insulinomimetic effects of C-peptide. Diabetologia 44:1247–1257PubMedCrossRef
131.
go back to reference Sima AAF, Wahren J (eds) (2009) The relevance of C-peptide in diabetes and its complications. Rev Diab Stud Special Issue 6:131–224 Sima AAF, Wahren J (eds) (2009) The relevance of C-peptide in diabetes and its complications. Rev Diab Stud Special Issue 6:131–224
132.
go back to reference Toth C, Schmidt AM, Tuor UI, Francis G, Foniok T, Brussee V, Kaur J, Yan SF, Martinez JA, Barber PA, Buchan A, Zochodne DW (2006) Diabetes, leukoencephalopathy and RAGE. Neurobiol Dis 23:445–461PubMedCrossRef Toth C, Schmidt AM, Tuor UI, Francis G, Foniok T, Brussee V, Kaur J, Yan SF, Martinez JA, Barber PA, Buchan A, Zochodne DW (2006) Diabetes, leukoencephalopathy and RAGE. Neurobiol Dis 23:445–461PubMedCrossRef
133.
go back to reference Winick M, Noble A (1965) Quantitative changes in DNA, RNA and protein during prenatal and postnatal growth in the rat. Dev Biol 12:451–466PubMedCrossRef Winick M, Noble A (1965) Quantitative changes in DNA, RNA and protein during prenatal and postnatal growth in the rat. Dev Biol 12:451–466PubMedCrossRef
134.
go back to reference Xu W, Qiu C, Winblad B, Fratiglioni L (2007) The effect of borderline diabetes on the risk of dementia and Alzheimer’s disease. Diabetes 56:211–216PubMedCrossRef Xu W, Qiu C, Winblad B, Fratiglioni L (2007) The effect of borderline diabetes on the risk of dementia and Alzheimer’s disease. Diabetes 56:211–216PubMedCrossRef
135.
go back to reference Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O’Brien PL, Palumbo PJ (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145:301–308PubMed Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O’Brien PL, Palumbo PJ (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145:301–308PubMed
136.
go back to reference Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes. Diabetes Care 27:1047–1053PubMedCrossRef Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes. Diabetes Care 27:1047–1053PubMedCrossRef
137.
go back to reference International Diabetes Federation (2000) Diabetes Atlas 2000. International Diabetes Federation, Brussels International Diabetes Federation (2000) Diabetes Atlas 2000. International Diabetes Federation, Brussels
138.
go back to reference Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M, Alzheimer’s Disease International (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112–2117PubMedCrossRef Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M, Alzheimer’s Disease International (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112–2117PubMedCrossRef
Metadata
Title
Encephalopathies: the emerging diabetic complications
Author
Anders A. F. Sima
Publication date
01-12-2010
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 4/2010
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-010-0218-0

Other articles of this Issue 4/2010

Acta Diabetologica 4/2010 Go to the issue